Skip to main content
Premium Trial:

Request an Annual Quote

Zyomyx in Antibody Deal with BD Biosciences

NEW YORK, July 30 – Protein chip maker Zyomyx of Hayward, Calif., said Monday it had entered into an agreement for access to BD Biosciences' antibody collection.

Under the terms of the deal, Zyomyx will have access to BD Biosciences' antibodies for use in protein biochip development. BD Biosciences will also develop other antibodies exclusively for Zyomyx. 

Zyomyx did not disclose financial terms of the agreement.

"This collaboration greatly expands Zyomyx' antibody resources and enhances our capability to develop superior protein biochips," Lawrence Cohen, CEO of Zyomyx, said in a statement.

Zyomyx is currently developing chips designed to detect up to 10,000 different proteins. The company has previously signed deals with Cambridge Antibody Technology and Dyax for access to their antibody resources and technologies.

Zyomyx previously said it planned to launch beta tests of its protein chips in the first half of 2001.

BD Biosciences of Franklin Lakes, NJ, is a division of Becton, Dickinson.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.